PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550617
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550617
Leber Congenital Amaurosis Market, By Treatment Type, By Target Gene, By End User, By Geography
The Global Leber Congenital Amaurosis Market is estimated to be valued at USD 1.23 Bn in 2024 and is expected to reach USD 1.68 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 1.23 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.50% | 2031 Value Projection: | US$ 1.68 Bn |
Leber congenital amaurosis (LCA) is a group of inherited retinal diseases causing severe visual impairment from birth. It is characterized by poor vision, nystagmus, and potentially blindness. LCA is typically caused due to mutations in genes responsible for photoreceptor development and retinal pigment epithelium function. As a result of progressive degeneration of photoreceptor cells, patients suffer from severe visual loss and blindness. Currently, there are no effective treatment options for LCA. However, gene therapy and retinal prosthetic devices hold promise to improve vision in affected individuals. The global LCA market is poised to grow significantly over the coming years driven by the development of novel therapeutics and devices.
Market Dynamics:
The global Leber congenital amaurosis market is projected to witness high growth over the next decade owing to several factors such as rising incidence of genetic retinal disorders, growing pipeline of gene therapy products and retinal prosthetic devices, and increasing research funding from government and non-profit organizations. However, lack of approved treatment options currently along with high cost of gene and cell-based therapies can hamper market growth. On the positive side, ongoing clinical trials evaluating gene therapies and increasing awareness about disease management provide significant opportunities in the market.
Key features of the study:
This report provides in-depth analysis of the global Leber congenital amaurosis market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, and competitive strategies adopted by key players
Key companies covered as part of this study include Spark Therapeutics, MeiraGTx Holdings plc, AGTC, ProQR Therapeutics N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Leber congenital amaurosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Leber congenital amaurosis market
Detailed Segmentation-
- By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
- By Target Gene Insights (Revenue, USD Bn, 2019 - 2031)
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
- By End-user Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
- By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis
- Biogen
- Spark Therapeutics
- GenSight Biologics
- Roche
- AbbVie
- Regeneron Pharmaceuticals
- Pfizer
- Astellas Pharma
- Santen Pharmaceutical
- Orphan Biovitrum
- Apellis Pharmaceuticals
- Gilead Sciences
- Eyenovia
- Avexis
- Regenxbio
- Horizon Therapeutics
- Aerie Pharmaceuticals
- Ophthotech Corporation
- Aldeyra Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Leber Congenital Amaurosis Market, By Treatment Type
- Global Leber Congenital Amaurosis Market, By Target Gene
- Global Leber Congenital Amaurosis Market, By End User
- Global Leber Congenital Amaurosis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Leber Congenital Amaurosis Market, By Treatment Type, 2024-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Pharmaceutical Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retinal Prosthesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Assistive Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Leber Congenital Amaurosis Market, By Target Gene, 2024-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- RPE65
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- GUCY2D
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- AIPL1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- RPGRIP1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- CEP290
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Other Genes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Leber Congenital Amaurosis Market, By End-User, 2024-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Specialized Eye Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Ophthalmology Research Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Leber Congenital Amaurosis Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Spark Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GenSight Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Santen Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orphan Biovitrum
- Apellis Pharmaceuticals
- Gilead Sciences
- Eyenovia
- Avexis
- Regenxbio
- Horizon Therapeutics
- Aerie Pharmaceuticals
- Ophthotech Corporation
- Aldeyra Therapeutics
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
